X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Gastroenterology Product Name: Xermelo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
With this agreement including the repayment of Lexicon’s secured loan concurrent with the closing of its sale of XERMELO®, Lexicon will have reduced the principal amount of its outstanding debt, supporting advancement of its LX9211 neuropathic pain program and other trials.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Gastroenterology Product Name: Xermelo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $62.5 million Upfront Cash: $41.0 million
Deal Type: Agreement September 23, 2020
Details:
As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Oncology Product Name: Xermelo
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TerSera
Deal Size: $224.0 million Upfront Cash: $159.0 million
Deal Type: Agreement July 30, 2020
Details:
Lexicon Pharmaceutical to present four posters highlighting XERMELO at the virtual Cholangiocarcinoma Foundation Annual Conference. XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor cells.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Oncology Product Name: Xermelo
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines were presented at the ASCO 2020 annual meeting.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
